H3 hemagglutinin proteins optimized for 2018 to 2022 elicit neutralizing antibodies across panels of modern influenza A(H3N2) viruses
The Journal of Immunology · 2025
DOI: 10.1093/jimmun/vkaf092 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von James D Allen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Florida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, FL, United States. Hauptthemen laut MEDLINE: Influenza A Virus, H3N2 Subtype, Hemagglutinin Glycoproteins, Influenza Virus, Influenza Vaccines, Antibodies, Viral. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Allergy and Infectious Diseases, NIH HHS, Collaborative Influenza Vaccine Innovations Centers.
Abstract (Originalsprache)
Influenza A(H3N2) viruses are currently evolving faster than any other subtype of seasonal influenza. As a result, vaccine efficacy can vary widely from one year to the next, and the wild-type antigens in the seasonal vaccine need to be updated frequently to stay current with the ever-changing viral landscape. To address this, 5 computationally optimized broadly reactive antigens (COBRAs) were designed from influenza A(H3N2) viruses that circulated during 2018 to 2022. These novel vaccine antigens incorporate important immunological epitopes from recently circulating viruses into one vaccine antigen providing the immune system with a variety of targets to elicit protective immune responses against. These computationally optimized H3 hemagglutinin vaccine antigens were first tested in immunologically naïve mice, in which they elicited antibodies with protective hemagglutination inhibition titers and neutralization activity against A(H3N2) vaccine strains from the last decade. Immune responses elicited by these vaccines were further enhanced in cohorts of mice and ferrets that were previously exposed to historical seasonal influenza viruses. In these animals, the COBRA HA antigens recalled epitopes recognized by influenza hemagglutinin–specific memory cells leading to stronger humoral immune responses. Incorporating these antigens into seasonal vaccines could improve protective efficacy in vaccinated individuals and reduce the need to reformulate vaccines annually.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Florida Research and Innovation Center, Cleveland Clinic, Port Saint Lucie, FL, United States.
- Department of Infection Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States.
- Center for Vaccines and Immunology, University of Georgia, Athens, GA, United States.
- Department of Infectious Diseases, University of Georgia, Athens, GA, United States.
Förderung
- National Institute of Allergy and Infectious Diseases
- NIH HHS
- Collaborative Influenza Vaccine Innovations Centers
- NIAID NIH HHS
- HHS
- Georgia Research Alliance
- National Institutes of Health
- Department of Health and Human Services
Zitieren
APA
Allen, J. D., Medina, J. M., Thomas, M. H., Lynch, A., Nelson, R., Aguirre, J., & Ross, T. M. (2025). H3 hemagglutinin proteins optimized for 2018 to 2022 elicit neutralizing antibodies across panels of modern influenza A(H3N2) viruses. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf092
Vancouver
Allen JD, Medina JM, Thomas MH, Lynch A, Nelson R, Aguirre J, et al. H3 hemagglutinin proteins optimized for 2018 to 2022 elicit neutralizing antibodies across panels of modern influenza A(H3N2) viruses. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf092
BibTeX
@article{Allen2025,
author = {Allen, James D and Medina, Jessica M and Thomas, Matthew H and Lynch, Amanda and Nelson, Ron and Aguirre, Julia and Ross, Ted M},
title = {H3 hemagglutinin proteins optimized for 2018 to 2022 elicit neutralizing antibodies across panels of modern influenza A(H3N2) viruses},
journal = {The Journal of Immunology},
year = {2025},
doi = {10.1093/jimmun/vkaf092}
}
EUVIMED